KR20010072564A - 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도 - Google Patents

루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도 Download PDF

Info

Publication number
KR20010072564A
KR20010072564A KR1020007011045A KR20007011045A KR20010072564A KR 20010072564 A KR20010072564 A KR 20010072564A KR 1020007011045 A KR1020007011045 A KR 1020007011045A KR 20007011045 A KR20007011045 A KR 20007011045A KR 20010072564 A KR20010072564 A KR 20010072564A
Authority
KR
South Korea
Prior art keywords
cells
antibody
cell
lupus
cd40cr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020007011045A
Other languages
English (en)
Korean (ko)
Inventor
랜돌프 제이. 노엘
크리스토퍼 엠. 번스
Original Assignee
존 에프. 카바나프
트러스티스 오브 다트마우스 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 존 에프. 카바나프, 트러스티스 오브 다트마우스 칼리지 filed Critical 존 에프. 카바나프
Publication of KR20010072564A publication Critical patent/KR20010072564A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020007011045A 1998-04-03 1999-04-02 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도 Ceased KR20010072564A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
US09/054,488 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
KR20010072564A true KR20010072564A (ko) 2001-07-31

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007011045A Ceased KR20010072564A (ko) 1998-04-03 1999-04-02 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도

Country Status (9)

Country Link
EP (1) EP1067954A4 (OSRAM)
JP (1) JP2002510643A (OSRAM)
KR (1) KR20010072564A (OSRAM)
CN (2) CN100352497C (OSRAM)
AU (1) AU743824B2 (OSRAM)
HU (1) HUP0101689A3 (OSRAM)
NO (1) NO20004966L (OSRAM)
TW (1) TWI224969B (OSRAM)
WO (1) WO1999051258A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EA201890434A1 (ru) 2015-08-05 2018-10-31 Янссен Байотек, Инк. Антитела к cd154 и способы их применения
SG10202111207TA (en) 2017-05-24 2021-11-29 Als Therapy Development Inst Therapeutic anti-cd40 ligand antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
NZ337072A (en) * 1997-01-10 2000-12-22 Biogen Inc use of an anti-CD40L compounds to inhibit the progression of nephritis, stabilize nephritis or reverse nephritis in a patient with an immune complex disease
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
CN1173735C (zh) 2004-11-03
HUP0101689A3 (en) 2004-08-30
NO20004966L (no) 2000-12-04
AU3379699A (en) 1999-10-25
EP1067954A1 (en) 2001-01-17
EP1067954A4 (en) 2004-08-18
CN100352497C (zh) 2007-12-05
TWI224969B (en) 2004-12-11
NO20004966D0 (no) 2000-10-02
JP2002510643A (ja) 2002-04-09
CN1757413A (zh) 2006-04-12
HUP0101689A2 (hu) 2001-08-28
WO1999051258A1 (en) 1999-10-14
AU743824B2 (en) 2002-02-07
CN1303301A (zh) 2001-07-11

Similar Documents

Publication Publication Date Title
JP4148537B2 (ja) Ｃｄ４０ｃｒレセプター及びそれに対するリガンド
Noelle et al. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells.
JP3833958B2 (ja) モノクローナル抗体５ｃ８が結合するタンパク質
HUP9904697A2 (hu) Eljárások és készítmények immunmodulációhoz
BR112019023138A2 (pt) anticorpo 4d anti-semaforina humano
US7476385B2 (en) Methods of inhibiting IgE responses to thymus-dependent antigens with the anti-gp39 antibody MR1
US6472510B1 (en) CD40 receptor ligands
AU7643094A (en) Methods of prolonged suppression of humoral immunity
AU743824B2 (en) Use of anti-gp39 antibodies for treatment and/or reversal of lupus and associated kidney disease
ES2301164T3 (es) Slam, antigeno coestimulador de la superficie de celulas t.
US20020058037A1 (en) Use of anti-gp-39 antibodies for treatment and/or reversal of lupus and lupus associated kidney disease
HK1067887A (en) Antibodies that bind the cd40cr receptor
US20060165689A1 (en) Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7
MXPA93000768A (en) Cd40cr receptor and ligands therefor
MXPA97003956A (en) Purified genes that codify antigens of surface of mammali cells, proteins and antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20001004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20020508

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040831

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050531

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040831

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20050830

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20050531

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20060930

Appeal identifier: 2005101005830

Request date: 20050830

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20050929

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20050830

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20041130

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20020508

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050830

Effective date: 20060930

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20060930

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20050830

Decision date: 20060930

Appeal identifier: 2005101005830